DNA strand and cancer cell in 3D

Sciety invests in cutting-edge biotech company NEOGAP Therapeutics

2021-12-22

PRESS RELEASE. Sciety recently made an investment of over SEK 58 million in the cell therapy company NEOGAP Therapeutics, which is developing personalised immunotherapy for the treatment of cancer. The new capital will be used for a clinical phase I/II trial in colorectal cancer with an estimated start in 2022.…

Läs mer
Knee pain abstract design

Sciety invests in Synartro that develops novel therapy for osteoarthritis

2021-10-25

PRESS RELEASE. The Swedish biotechnology company Synartro, which is developing a novel, improved treatment for knee osteoarthritis, has successfully raised SEK 34 million with Sciety and its investment syndicate. The new capital will be used for the company’s first clinical trial expected to start in 2022. ”We greatly appreciate the…

Läs mer

The Sciety syndicate and Segulah Medical Acceleration invest MSEK 106 in SAGA Diagnostics

2021-06-30

PRESS RELEASE. The Swedish diagnostics company SAGA Diagnostics, which develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment, recently completed a share issue of SEK 106 million led by Segulah Medical Acceleration together with Sciety. Hadean Ventures, which invested in the company at an…

Läs mer
Man with knee pain is being examined by a physiotherapist.

Company that develops novel osteoarthritis treatment raises capital with Sciety

2021-05-05

NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain and disability in Europe and the US. Only half of the patients receive adequate pain relief. Sciety is now financing a company whose drug candidate has the potential to provide…

Läs mer
Bild på lunga med tuberkulos och närbild på mycobacterium tuberculosis.

49 MSEK to EMPE Diagnostics with focus on rapid tuberculosis diagnostics

2021-02-09

EMPE Diagnostics, which has developed a rapid test for the diagnosis and resistance determination of tuberculosis, the world’s deadliest infectious disease, has recently completed a share issue of SEK 23.5 million with Sciety. The company has also received a grant of SEK 25 million from EU Horizon 2020. The new…

Läs mer

The Sciety syndicate invests MSEK 31 in Capitainer

2021-01-18

PRESS RELEASE. Capitainer, a Swedish Medtech company that supplies intelligent solutions for self-sampling of blood and plasma, recently completed a share issue of SEK 31 million with Sciety and its investment syndicate. The investors demonstrated strong interest, and the share issue was fully subscribed in two days. The new capital…

Läs mer

Company that develops innovative blood sampling raises capital with Sciety

2020-11-24

NEW COMPANY AT SCIETY. Most blood sampling is still performed by qualified healthcare personnel at care facilities, but new technology that enables simple and reliable home sampling is now changing the landscape. Sciety finances a Swedish company that is at the forefront of the technology shift. Blood sampling has an…

Läs mer

Cartana is acquired by 10x Genomics for 425 MSEK

2020-09-11

PRESS RELEASE. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago.   Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology.…

Läs mer

Interview with Mats Nilsson, serial entrepreneur at SciLifeLab

2020-05-18

Sciety had the opportunity to ask a few questions to Mats Nilsson, professor at SciLifeLab and co-founder of EMPE Diagnostics and several other biotechnology companies. In the interview he talks about EMPE Diagnostics’ planned establishment in India and and about the need for diagnostic tools in order to use the drugs that are available. He gives an insight into SciLifeLab as the platform for developing ideas and also his view on the role of research in society.

Läs mer

The Sciety syndicate invests in Synartro that develops a novel drug for osteoarthritis

2020-05-04

The Sciety syndicate invests in Synartro, which uses existing drugs with proven efficacy to develop an improved drug treatment of knee osteoarthritis. The new capital will be used to complete the pre-clinical development. The company plans to go public to raise capital for phase 1 clinical trials in 2021. Synartro’s…

Läs mer